TABLE 2
FROM:
Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients
E T Korthof, P P Snijder, A A de Graaff, A C Lankester, R G M Bredius, L M Ball, J L W T Lie, J M Vossen and R M Egeler
BACK TO ARTICLETable 2. Conditioning regimen, donor, T-cell depletion, cell dose and GvHD prophylaxis
| UPN | Conditioning | Donor a | TCD |
NC  108/kg
b
| GvHD prophylaxis |
|---|---|---|---|---|---|
| 031 | CY, BU, Hydroxyurea, TBI | MSD | No | 4.0 | MTX |
| 036 | CY, TBI | MSD | No | 4.0 | MTX |
| 107 | CY, TBI | MSD | No | 3.0 | CyA/MTX |
| 140.1 | CY, TBI | MSD | No | 3.5 | CyA/MTX |
| 177 | Ara-C, CY, TBI | MSD | No | 2.5 | CyA/MTX |
| 194 | Ara-C, Etoposide, BU, CY | MSD | No | 2.8 | CyA/MTX |
| 196 | Etoposide, BU, CY | MSD | No | 4.0 | CyA/MTX |
| 210.1 | Ara-C, CY, Campath, anti-LFA1, TBI | MMUD | Yes | 4.0 | CyA/MTX |
| 226 | Ara-C, CY, Campath, anti-LFA1, TBI | MMUD | Yes | 4.3 | None |
| 240 | Ara-C, CY, TBI | MSD | No | 4.6 | CyA/MTX |
| 272 | Ara-C, CY, Campath, anti-LFA1, TBI | MMUD | Yes | 1.0 | MTX |
| 273 | Ara-C, CY, Campath, anti-LFA1, TBI | MMUD | Yes | 2.5 | MTX |
| 298 | Ara-C, Etoposide, CY, Campath, TBI | MUD | No | 5.3 | CyA/MTX |
| 329 | BU, CY | MMRD | No | 4.8 | CyA/MTX |
| 339 | BU, CY, Melphalan | MSD | No | 1.5 | CyA/MTX |
| 355 | BU, CY, Melphalan | MSD | No | 2.8 | CyA/MTX |
| 369 | Ara-C, CY, TBI | MMRD | No | 2.3 | CyA/MTX |
| 372 | Ara-C, CY, TBI | MMRD | No | 3.2 | CyA/MTX |
| 412 | BU, CY, Melphalan, Campath | MUD | No | 11.0 | CyA/MTX |
| 419 | BU, CY, Melphalan, Campath | MUD | No | 2.2 | CyA/MTX |
| 430 | CY, Melphalan, Campath, anti-LFA1, TBI | MMUD | Yes | 0.8 | CyA |
| 445 | BU, CY, Melphalan, Campath | MUD | No | 3.2 | CyA/MTX |
| 450.1 | BU, CY, Melphalan | MSD | No | 5.3 | CyA/MTX |
a MSD=matched sibling donor; MUD=matched unrelated donor; MMUD=mismatched unrelated donor; MMRD=mismatched related donor.
b Number of nucleated cells in bone marrow harvest.
